Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build ...

The news sparked a near-5% rise in Novartis’ share price. Chief executive Vas Narasimhan said performance was good “across all key growth brands and geographies” and “gives us continued ...

Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront. The Italian ...

In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.

I was at Novartis headquarters in Basel yesterday ... While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal ...

Novartis said this morning that Bradner (pictured ... could see a headcount reduction of 8,000 as chief executive Vas Narasimhan chases down $1.5 billion in cost reductions.